Adaptive Biotechnologies Q2 net loss widens to $39.9 million; revenue rises 22% to $71.6 million
ADPT•Outlook and guidance
Non-GAAP adjusted EBITDA loss narrowed to $0.7 million from a loss of $7.2 million a year earlier.
Adaptive Biotechnologies raised full-year 2026 MRD revenue guidance to $268 million-$278 million and announced plans to separate MRD and Immune Medicine.
Second-quarter results
Adaptive Biotechnologies posted second-quarter revenue of $71.6 million, up 22% year over year, while net loss widened to $39.9 million.
MRD revenue rose 33% to $66.2 million, making up 92% of revenue; Immune Medicine revenue fell 40% to $5.4 million.
clonoSEQ test volume increased 43% to 36,111 tests delivered.
